Camber Capital Management’s Theravance Biopharma TBPH Stock Holding History

Camber Capital Management’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$4.96M	Sell	450,000 -550,000	-55%	-$5.35M	0.47%	23
2025 Q1	$8.93M	Hold	1,000,000	–	–	0.32%	27
2024 Q4	$9.41M	Hold	1,000,000	–	–	0.22%	37
2024 Q3	$8.06M	Hold	1,000,000	–	–	0.26%	30
2024 Q2	$8.48M	Hold	1,000,000	–	–	0.23%	34
2024 Q1	$8.97M	Buy	+1,000,000	New	+$9.27M	0.22%	33
2022 Q1	–	Sell	-500,000	Closed	-$5.53M	–	45
2021 Q4	$5.53M	Sell	500,000 -2,000,000	-80%	-$17.4M	0.19%	35
2021 Q3	$18.5M	Buy	+2,500,000	New	+$28M	0.57%	37

Other funds holding TBPH

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ICM

Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

OMC

Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Camber Capital Management's TBPH Position: Q2 2025 in Review

Camber Capital Management reduced its Theravance Biopharma (TBPH) stake by 55% in Q2 2025, selling an estimated $5.35M and leaving 450,000 shares worth $4.96M. The position accounts for 0.47% of the portfolio, ranked #23.

Camber Capital Management first reported a position in TBPH in Q3 2021 and has held it in 8 quarters since. The position peaked at $18.5M in Q3 2021. 135 funds tracked by Wall St. Rank hold TBPH as of Q2 2025.

Camber Capital Management held 450,000 shares of Theravance Biopharma worth $4.96M as of Q2 2025.
Camber Capital Management sold 550,000 Theravance Biopharma shares in Q2 2025, an estimated $5.35M.
Theravance Biopharma made up 0.47% of Camber Capital Management's portfolio in Q2 2025, its #23 holding.
Camber Capital Management first reported a position in Theravance Biopharma in Q3 2021 and has held it in 8 quarters since.
Camber Capital Management's Theravance Biopharma position peaked at $18.5M in Q3 2021.
135 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2025.

Based on Camber Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.